{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:10:51Z","timestamp":1684469451159},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1038\/sj.bjc.6602267","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T19:26:58Z","timestamp":1107890818000},"page":"47-54","source":"Crossref","is-referenced-by-count":7,"title":["The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer"],"prefix":"10.1038","volume":"92","author":[{"given":"R S","family":"Day","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S E","family":"Shackney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W P","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,1,14]]},"reference":[{"key":"BF6602267_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0959-8049(00)00347-6","volume":"37","author":"KH Antman","year":"2001","unstructured":"Antman KH (2001) A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur J Cancer 37: 173\u2013179","journal-title":"Eur J Cancer"},{"key":"BF6602267_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0093-7754(01)90131-9","volume":"28","author":"RD Baynes","year":"2001","unstructured":"Baynes RD, Dansey RD, Klein JL, Hamm C, Campbell M, Abella E, Peters WP (2001) High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 28: 377\u2013388","journal-title":"Semin Oncol"},{"key":"BF6602267_CR3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0140-6736(00)02841-5","volume":"356","author":"J Bergh","year":"2000","unstructured":"Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384\u20131391","journal-title":"Lancet"},{"key":"BF6602267_CR4","volume-title":"Empirical Model Building and Response Surfaces","author":"GP Box","year":"1987","unstructured":"Box GP, Draper NR (1987) Empirical Model Building and Response Surfaces. New York: John Wiley & Sons"},{"key":"BF6602267_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","volume":"90","author":"DR Budman","year":"1998","unstructured":"Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205\u20131211","journal-title":"J Natl Cancer Inst"},{"key":"BF6602267_CR6","volume-title":"Cancer Medicine","author":"C Dang","year":"2003","unstructured":"Dang C, Gilewski T, Surbone A, Norton L (2003) Cytokinetics. In Cancer Medicine Kufe DW, Pollock R, Weichselbaum R, Bast R, Holland J, Frei III E (eds) Chapter 38, 6th edition, online through \n                    www.ncbi.nlm.nih.gov\/books\n                    \n                  . Dekker Inc, Hamilton, Ontario, BC"},{"key":"BF6602267_CR7","unstructured":"Early Breast Cancer Trialists' Collaborative Group (2004) Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev CD 000487"},{"key":"BF6602267_CR8","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.1999.17.11.3374","volume":"17","author":"B Fisher","year":"1999","unstructured":"Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N (1999) Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17: 3374\u20133388","journal-title":"J Clin Oncol"},{"key":"BF6602267_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0093-7754(01)90042-9","volume":"28","author":"L Gianni","year":"2001","unstructured":"Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bonadonna G (2001) Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 28: 13\u201329","journal-title":"Semin Oncol"},{"key":"BF6602267_CR10","first-page":"1210","volume":"51","author":"WM Gregory","year":"1991","unstructured":"Gregory WM, Richards MA, Slevin ML, Souhami RL (1991) A mathematical model relating response durations to amount of subclinical resistant disease. Cancer Res 51: 1210\u20131216","journal-title":"Cancer Res"},{"key":"BF6602267_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/jnci\/92.3.225","volume":"92","author":"GN Hortobagyi","year":"2000","unstructured":"Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE (2000) Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92: 225\u2013233","journal-title":"J Natl Cancer Inst"},{"key":"BF6602267_CR12","first-page":"15","volume":"30","author":"AK Laird","year":"1969","unstructured":"Laird AK (1969) Dynamics of growth in tumors and in normal organisms. Natl Cancer Inst Monogr 30: 15\u201328","journal-title":"Natl Cancer Inst Monogr"},{"key":"BF6602267_CR13","first-page":"7067","volume":"48","author":"L Norton","year":"1988","unstructured":"Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067\u20137071","journal-title":"Cancer Res"},{"key":"BF6602267_CR14","first-page":"101","volume-title":"National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer","author":"WP Peters","year":"2000","unstructured":"Peters WP, Rosner G, Hurd D, Norton L, Schilsky R (2000) A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082\/SWOG 9114\/NCIC MA-13. In National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer pp 101. Bethesda, MD: National Institutes of Health"},{"key":"BF6602267_CR15","unstructured":"Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L (1999) A prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082\/SWOG 9114\/NCIC MA-13. Proceedings of the American Society of Clinical Oncology"},{"key":"BF6602267_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/107327480301000105","volume":"10","author":"H Roche","year":"2003","unstructured":"Roche H, Viens P, Biron P, Lotz JP, Asselain B (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10: 42\u201347","journal-title":"Cancer Control"},{"key":"BF6602267_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMoa022794","volume":"349","author":"S Rodenhuis","year":"2003","unstructured":"Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349: 7\u201316","journal-title":"N Engl J Med"},{"key":"BF6602267_CR18","first-page":"1","volume":"35","author":"H Skipper","year":"1964","unstructured":"Skipper H, Schabel FM, Wilcox W (1964) Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with \u2018curability\u2019 of experimental leukemia. Cancer Chemother Rep 35: 1\u2013111","journal-title":"Cancer Chemother Rep"},{"key":"BF6602267_CR19","first-page":"5","volume":"45","author":"H Skipper","year":"1965","unstructured":"Skipper H, Schabel FM, Wilcox W (1965) Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 45: 5\u201328","journal-title":"Cancer Chemother Rep"},{"key":"BF6602267_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/sdr.261","volume":"18","author":"JD Sterman","year":"2002","unstructured":"Sterman JD (2002) All models are wrong: reflections on becoming a systems scientist. System Dyn Rev 18: 501\u2013531","journal-title":"System Dyn Rev"},{"key":"BF6602267_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMoa030684","volume":"349","author":"MS Tallman","year":"2003","unstructured":"Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349: 17\u201326","journal-title":"N Engl J Med"},{"key":"BF6602267_CR22","doi-asserted-by":"crossref","unstructured":"The French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19: 602\u2013611","DOI":"10.1200\/JCO.2001.19.3.602"},{"key":"BF6602267_CR23","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1200\/JCO.2004.07.026","volume":"22","author":"AR Zander","year":"2004","unstructured":"Zander AR, Kroger N, Schmoor C, Kruger W, Mobus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH, Janicke F, Schumacher M, Jonat W (2004) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22: 2273\u20132283","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602267","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:13:38Z","timestamp":1684412018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["BF6602267"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602267","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}